MBX Biosciences(MBX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MBX MBX Biosciences

交易中 11-22 13:04:46 EST

17.22

+0.71

+4.27%

最高18.29	最低16.75	成交量4.27万
今开16.75	昨收16.51	日振幅9.33%
总市值5.75亿	流通市值2.38亿	总股本3,342万
成交额74.84万	换手率0.31%	流通股本1,385万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":17.215,"timestamp":1732298666488,"preClose":16.51,"halted":0,"volume":42730,"delay":0,"floatShares":13851706,"shares":33417418,"eps":-4.007686,"marketStatus":"交易中","marketStatusCode":2,"change":0.705,"latestTime":"11-22 13:04:46 EST","open":16.75,"high":18.29,"low":16.75,"amount":748372.49359,"amplitude":0.093277,"askPrice":17.35,"askSize":161,"bidPrice":17.08,"bidSize":303,"shortable":3,"etf":0,"ttmEps":-4.007686,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732309200000},"adr":0,"listingDate":1726200000000,"adjPreClose":16.51,"preHourTrading":{"tag":"盘前","latestPrice":16.36,"preClose":16.51,"latestTime":"08:54 EST","volume":2,"amount":31.560002,"timestamp":1732283652914},"postHourTrading":{"tag":"盘后","latestPrice":16.51,"preClose":16.51,"latestTime":"16:00 EST","volume":496,"amount":8188.96,"timestamp":1732222804987},"volumeRatio":0.501763},"requestUrl":"/m/hq/s/MBX","defaultTab":"news","newsList":[{"id":"2482177892","title":"莱尔德热系统宣布推出用于下一代光电设备的全新微型热电制冷器产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2482177892","media":"赛迪网","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482177892?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:18","pubTimestamp":1731403118,"startTime":"0","endTime":"0","summary":"莱尔德热系统宣布扩展微型热电制冷器产品线，并推出OptoTEC MBX系列，该系列适用于空间受限的高性能光电应用。MBX系列具有高达43 W/cm2的高热泵密度，在50℃环境温度下可实现高达82℃温差。MBX系列可依照客户要求进行客制化设计，满足特定的外形尺寸、热泵密度和制冷效率等要求。莱尔德热系统还可提供多种特殊的表面处理选项，包括镀金图案、热敏电阻附件和密封，以适应那些非密封设备。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112172506abb98c2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112172506abb98c2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1978683503.SGD","BK4585","LU0124384867.USD","BK4161","BK4007","MBX","LU0256863902.USD","BK4588","SG9999001440.SGD","LU0417517546.SGD","IR","LU0256863811.USD"],"gpt_icon":0},{"id":"2477636551","title":"更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477636551","media":"路透中文","labels":["Shareholding Changes","Product Release","event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477636551?lang=zh_cn&edition=full","pubTime":"2024-10-24 20:08","pubTimestamp":1729771713,"startTime":"0","endTime":"0","summary":"更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元第 3-5 段补充了生物技术行业的背景，第 6-7 段补充了 Septerna 的主要药物。路透10月24日 - 高盛支持的药物开发商赛普特纳公司周四表示，该公司将在美国进行规模更大的首次公开募股，寻求获得 7.431 亿美元的估值，这表明投资者对这一资本密集型行业的乐观情绪。高盛持有 Septerna 5.4% 的股份，该公司目前的目标是通过出售近 1530 万股每股 18 美元的股票筹集 2.75 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241024:nL4S3M01LN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes,Product Release,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","LU0106831901.USD","IE0002270589.USD","IE0004086264.USD","BK4588","LU2237438978.USD","BK4552","IE00B19Z3581.USD","BK4139","IE0004091025.USD","LU2237443622.USD","LU2237443465.HKD","BCAX","IE00B19Z3B42.SGD","LU2237443978.SGD","MBX","BK4007","LU2237443895.HKD","IE00BSNM7G36.USD","UPB","BK4127","LU2237443382.USD","IE00BFXG1179.USD","BK4585","BK4504","BK4533","LU1791807156.HKD","BIOA","LU1668664300.SGD","LU2237443549.SGD","BK4550"],"gpt_icon":0},{"id":"2473413859","title":"美国研究综述-人本、波蒂略、沃特斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2473413859","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473413859?lang=zh_cn&edition=full","pubTime":"2024-10-08 14:58","pubTimestamp":1728370686,"startTime":"0","endTime":"0","summary":"    路透10月8日 - 华尔街证券分析师周二调整了对几家在美国上市的公司的评级和目标价，其中包括人福网、波特罗和沃特斯。* 沃特斯公司  ：杰富瑞将其评级从 \"持有 \"上调至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0640476718.USD","LU0323591593.USD","CMG","LU1153585028.USD","ACR","LU0496365809.HKD","SHW","BIIB","PPG","LGIH","PSX","PZZA","IE0034235188.USD","LU1791807156.HKD","LU2264538146.SGD","LU1244550494.USD","BK4550","IE00B1BXHZ80.USD","WING","LU0354030438.USD","LU0109391861.USD","LU1093756325.SGD","LU1267930490.SGD","LU0256863811.USD","OWL","LU1923622614.USD","WAT","BK4516","LU0215105999.USD","CVX","LU0868494708.USD","LU0278409577.USD","LU0061475181.USD","LU1244550577.SGD","PTLO","BK4592","HUM","LU0353189680.USD","LFCR","SG9999014021.USD","HOLX","IE00B775SV38.USD","BK4534","MBX","SCHW","LU1983260115.SGD","LU0170899867.USD","LU0211328371.USD"],"gpt_icon":1},{"id":"1154740936","title":"异动解读 | MBX生物科学上市同日大涨53% 投资者看好其减肥新药前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1154740936","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154740936?lang=zh_cn&edition=full","pubTime":"2024-09-14 11:06","pubTimestamp":1726283190,"startTime":"0","endTime":"0","summary":"MBX生物科学公司在纳斯达克上市首日即大获成功,股价大涨53.25%,收于23.65美元,引发市场广泛关注。该公司聚焦内分泌和代谢疾病的创新治疗,正在开发一系列候选药物以应对糖尿病、肥胖等常见疾病,上市股价表现耀眼反映了投资者对公司前景的高度认可。MBX生物科学最值得关注的是其肥胖候选药物MBX 4291,这一长效创新疗法有望成为新一代高效减肥药。未来若候选药物顺利商业化,MBX生物科学将捕获可观的发展机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MBX"],"gpt_icon":0},{"id":"2467867056","title":"生物医药公司MBX纳斯达克上市：大涨48% 公司市值7亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467867056","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467867056?lang=zh_cn&edition=full","pubTime":"2024-09-14 11:04","pubTimestamp":1726283096,"startTime":"0","endTime":"0","summary":"生物医药公司MBX Biosciences（股票代码：“MBX”）昨日在美国纳斯达克上市。MBX Biosciences发行价为16美元，发行1020万股，募资总额为1.63亿美元。MBX Biosciences开盘价为23美元，较发行价上涨44%；收盘价为23.65美元，较发行价上涨47.81%；以收盘价计算，公司市值为7.13亿美元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240914/6386190868877293219063255.png","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240914/6386190868877293219063255.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.leinews.com/n27758/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["ARTL","PSQ","NQmain","MBX","03086","BK1147","QID",".IXIC","MNQmain","TQQQ","QLD","SQQQ","BK4007"],"gpt_icon":1},{"id":"1159152248","title":"异动解读 | 研发减肥新药 MBX生物科学上市首日大涨44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159152248","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159152248?lang=zh_cn&edition=full","pubTime":"2024-09-14 00:38","pubTimestamp":1726245495,"startTime":"0","endTime":"0","summary":"MBX生物科学公司(MBX Biosciences)周五在纳斯达克上市首日即大获成功,股票大涨43.88%,收于20.11美元。\n\nMBX生物科学是一家新兴的生物制药公司,正专注于开发针对内分泌和代谢紊乱的疗法,包括糖尿病和肥胖症等常见疾病。公司研发管线中有多个候选药物品种,预期将有助于调节体内胰岛素等重要激素的水平,从而改善患者的症状。\n\n分析人士认为,MBX生物科学在上市首日股价大涨,反映了市场投资者对该公司减肥新药以及整体业务前景的看好。近年来,糖尿病和肥胖人群不断增加,减肥新药需求旺盛,为这家新兴生物科技公司提供了广阔的市场发展空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MBX"],"gpt_icon":0},{"id":"2467703732","title":"MBX 生物科学公司股价大涨 44%，在纳斯达克首次亮相即大获成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2467703732","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467703732?lang=zh_cn&edition=full","pubTime":"2024-09-14 00:32","pubTimestamp":1726245178,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透9月13日 - MBX生物科学公司  正在开发针对内分泌和代谢紊乱（包括糖尿病和肥胖症）的疗法，该公司股票周五在 纳斯达克首次上市时 上涨了近44%，凸显了投资者对减肥药物的关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QID","TQQQ","BK4007","MBX","SQQQ","PSQ",".IXIC","ARTL","MNQmain","NQmain","QLD"],"gpt_icon":1},{"id":"2467375509","title":"MBX 生物科学公司在美国首次公开募股中筹资 1.632 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467375509","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467375509?lang=zh_cn&edition=full","pubTime":"2024-09-13 07:18","pubTimestamp":1726183122,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透9月12日 - 正在开发治疗糖尿病和肥胖症等内分泌和新陈代谢疾病的多肽疗法的 MBX 生物科学公司周四表示，该公司在美国的首次公开募股已筹集到 1.632 亿美元。这家生物技术公司以每股16美元的价格发行了1020万股股票，处于每股14至16美元目标区间的高端。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mbxbio.com","stockEarnings":[{"period":"1week","weight":-0.1529},{"period":"1month","weight":-0.3112},{"period":"3month","weight":0.0319},{"period":"ytd","weight":0.0319}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MBX Biosciences, Inc.于2018年8月在印第安纳州成立，并于2019年4月转变为特拉华州公司。他们是一家临床阶段的生物制药公司，专注于发现和开发治疗内分泌和代谢疾病的新型精准肽疗法。他们的公司由全球领导者创立，采用变革性的方法进行肽药物的设计和开发。利用这一专业知识，他们设计了自己的专有精密内分泌肽（PEPTM）平台，以克服未修饰和修饰肽疗法的关键局限性，改善临床结果，简化患者的疾病管理。","exchange":"NASDAQ","name":"MBX Biosciences","nameEN":"MBX Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MBX Biosciences(MBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MBX Biosciences(MBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MBX Biosciences,MBX,MBX Biosciences股票,MBX Biosciences股票老虎,MBX Biosciences股票老虎国际,MBX Biosciences行情,MBX Biosciences股票行情,MBX Biosciences股价,MBX Biosciences股市,MBX Biosciences股票价格,MBX Biosciences股票交易,MBX Biosciences股票购买,MBX Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MBX Biosciences(MBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MBX Biosciences(MBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}